← back to search

Veerle Bossuyt

Brigham and Women's Hospital · US
Area of research
Oncology · Cancer Research
Research interest
Research interests include HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers, Breast Cancer Treatment Studies, and Breast Lesions and Carcinomas.
h-index
29
citations
5,912
works
150
NIH funding
primary concept
Medicine
email

Recent publications

Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Clinical Cancer Research 2024cited by 40position: middledoi
Metaplastic breast cancer: A review
Critical Reviews in Oncology/Hematology 2023cited by 51position: middledoi
Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
Modern Pathology 2020cited by 129position: middledoi
Increased epigenetic age in normal breast tissue from luminal breast cancer patients
Clinical Epigenetics 2018cited by 65position: middledoi
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Advances in Anatomic Pathology 2017cited by 795position: middledoi
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Advances in Anatomic Pathology 2017cited by 713position: middledoi
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
Seminars in Cancer Biology 2017cited by 429position: middledoi
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group
Modern Pathology 2015cited by 282position: middledoi
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
Annals of Oncology 2015cited by 237position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Laura M. Spring · Harvard University2 papers (2023–2024)Lajos Pusztai · Yale University2 papers (2018–2020)Anees B. Chagpar · Brown University1 papers (2018–2018) · 1 papers (2024–2024)Beverly Moy · Harvard University1 papers (2024–2024)Omar Hameed · University of Alabama at Birmingham1 papers (2020–2020)Bogang Wu · Jinan University1 papers (2024–2024) · 1 papers (2024–2024)J. Michael Dixon · NHS Lothian1 papers (2015–2015)Seth A. Wander · Harvard University1 papers (2024–2024)Kamaljeet Singh · Providence College1 papers (2020–2020)Lianne Epstein · Yale Cancer Center1 papers (2018–2018)David L. Rimm · Yale Cancer Center1 papers (2020–2020)Beth Harrison · New York University1 papers (2020–2020)Fahad Shabbir Ahmed · Indiana University School of Medicine1 papers (2020–2020)Judy C. Boughey · Mayo Clinic1 papers (2015–2015)Carsten Denkert · Frankfurt Cancer Institute1 papers (2015–2015)D. Dalela · Yale Cancer Center1 papers (2018–2018)Anja C. Roden · Mayo Clinic1 papers (2020–2020)Aditya Bardia · Comprehensive Blood & Cancer Center1 papers (2024–2024)